Post-Approval Study of the Guidant Carotid Stent Systems and Embolic Protection Systems: CAPTURE
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00180492|
Recruitment Status : Completed
First Posted : September 16, 2005
Last Update Posted : October 29, 2008
|Condition or disease||Intervention/treatment||Phase|
|Atherosclerotic Disease, Carotid||Device: RX ACCULINK(TM) Carotid Stent System and RX ACCUNET(TM) Embolic Protection System||Not Applicable|
CAPTURE is a post-approval study to collect information on the safety and effectiveness of the ACCULINK and ACCUNET since the approval/clearance of these devices by the FDA. The ACCULINK stent is an elastic-like metal tube that is used to hold open a narrow part of a blood vessel. The ACCUNET is a wire mesh basket that is placed in the vessel to catch material (blood clots, fatty material) that could break off from the narrowed area of the blood vessel and block blood flow downstream during the stent procedure.
Another goal of the CAPTURE study is to confirm that the ACCULINK and ACCUNET can be used safely by physicians with varying levels of experience in stenting procedures.
The basis for FDA's approval/clearance of the ACCULINK and ACCUNET was the ARCHeR trials (ACCULINK/ACCUNET for Revascularization of Carotids in High-Risk Patients). The ARCHeR trials were conducted to collect data on the safety and effectiveness of the ACCULINK and ACCUNET when used in the treatment of carotid artery disease in patients at high risk for surgical treatment (carotid endarterectomy) because of medical or surgical comorbidities. The ARCHeR trials showed that the ACCULINK, used with or without the ACCUNET, is a safe and effective treatment option based on the rate of death, stroke, and myocardial infarction at 30 days, and stroke at one year.
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||1500 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Carotid RX ACCULINK(TM)/ACCUNET(TM) Post-Approval Trial to Uncover Unanticipated or Rare Events - CAPTURE|
|Study Start Date :||October 2004|
|Actual Primary Completion Date :||December 2006|
|Actual Study Completion Date :||August 2007|
- Death, stroke, and myocardial infarction at 30 days post-procedure.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00180492
|United States, California|
|Santa Clara, California, United States, 95054|
|Study Chair:||Gary A Walker, PhD||Abbott Vascular|